3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
5
Fallopian Tube Neoplasms
5
Breast Neoplasms
5
Endometrial Neoplasms
4
Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Prostate Cancer Metastatic
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma, Malignant
1
Leiomyosarcoma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma, Clear Cell
1
Adenocarcinoma of the Oesophagus
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
ATM Gene Mutation
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
rucaparib
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled